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Introduction
Over the last two decades, clinical nutrition has evolved from 
nutritional support that is intended to meet the patient’s needs 
only (denoting a passive role), to nutrition therapy that is selected 
according to the patient’s disease or medical condition. Currently, 
there is renewed interest in nutritional therapy in critical illness, 
particularly in the areas of immunonutrition and pharmaconutrition 
(or nutritional pharmacology).1 It is now known that nutrition is much 
more than just delivering basic substrates or nutrients that play a 
role in providing a fuel source for basic metabolism and cell growth, 
but that there are specific nutrients, or combinations thereof, that 
can reduce the risk of infection and improve outcomes in critically 
ill patients.2
Immunonutrition has been described as the ability to modulate the 
inflammatory or immune response by nutrients or a specific food 
item that is fed in amounts above what is normally consumed 
through the diet alone.3,4 Furthermore, some nutrients, when given 
in higher doses, appear to serve as pharmacological agents. In the 
latter context, these pharmaconutrients may positively or negatively 
alter clinical outcomes in a manner that is not dissimilar to the way 
in which any other pharmacological agent functions.1,5,6 
The earliest scientific evidence that implicates the role of nutrition in 
immune function is probably the description of thymic atrophy that 
was provided by Menkel in 1810.7 The birth of nutritional immunology 
(1800s) and the vitamin era (1900s) improved our understanding 
of the impact of nutritional deficiencies on the immune system.7 
Some of the pioneering work in immunonutrition was carried out 
by Alexander at the Shriners Burns Institute. His research led to the 
formulation of the Shriners’ burn formula, an enteral (EN) feeding 
solution that contained arginine, ω-3 fatty acids (FAs), and vitamins 
A, C and zinc.8 This formula resulted in reduced length of stay and 
reduced wound infections.9 Thus immunonutrition is not a new 
concept as it is often regarded, but rather the application thereof to 
new clinical settings.
The purpose of this article is not to provide an exhaustive review of 
the available literature on immunonutrition, but rather to highlight 
key and recent significant studies and relate them to the South 
African context. One of the restricting factors in providing state-
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of-the-art health care in South African is limited available finances. 
Often immunonutrition is perceived to be expensive when compared 
with standard enteral (EN) and parenteral (PN) products. Healthcare 
providers need to be more aware of the evidence base that supports 
the benefits of immunonutrition in defined populations, and that such 
an approach could ultimately result in cost saving, when prescribed 
correctly.
The critical care patient population
The population in the intensive care unit (ICU) is heterogeneous in 
nature. This diverse population suffers severe physiological stress 
or organ failure with varying degrees of acute phase response, 
insulin resistance and hyperglycaemia, protein loss, impaired gut 
function and immune system alterations. It has been suggested 
that the metabolic response after injury should be divided into 
three distinct phenotypes: the ischaemia-reperfusion phenotype, 
leucocyte phenotype and angiogenic phenotype.10 This may help 
to determine the best nutrition therapy for patients in a specific 
category. Furthermore, it has been consistently documented 
that approximately 15-70% of patients are undernourished 
or malnourished on admission to hospital,11-16 which further 
complicates the provision of optimal nutrition therapy. Against this 
heterogeneity, while the provision of nutrients to meet requirements 
remains of paramount importance, it might be considered simplistic 
that the “one nutrition therapy regimen will fit all” approach can 
provide optimal therapeutic support. 
What is to be achieved?
In part, the goal of the nutrition therapy dietitian or practitioner could 
be described as supplying the best possible nutrition therapy to 
the patient to aid the recovery process, prevent complications and 
discharge a functional patient home. This encompasses screening 
and assessing, as well as supplying the correct amount and mix of 
nutrients to support and modulate the acute phase response and 
immune system, and maintain and improve nutritional status. Due 
to high demand and cost of care, the overall objective remains 
minimising the duration and costs of hospitalisation, while still trying 
to provide optimal care. This raises the question whether or not these 
goals are mutually exclusive since immunonutrition is deemed to be 
expensive.
By preventing and managing the complications of malnutrition, 
nutrition therapy dietitians contribute significantly to lowering 
care costs. Protein-energy malnutrition (PEM) has been shown to 
be an independent risk factor for morbidity and mortality. PEM is 
associated with a significantly higher risk of complications, such as 
infection, increased mortality, increased length of stay in hospital 
and ICU, decreased quality of life and poorer prognosis, all of which 
have been shown to increase care costs.11,16-19 In this regard, despite 
the respective limitations of the reported studies, the consistency of 
the reported findings (Table I) may be more important than the actual 
costs, which are country-dependent. In addition, malnutrition is also 
associated with impaired cell-mediated immunity with changes in 
peripheral lymphocyte subsets, as well as increased cortisol levels 
and T-helper 1 to T-helper 2 cytokine shift.20 Furthermore, unplanned 
readmission of medical patients has been shown to be associated 
with chronic disease, depressive symptoms and underweight.21
The South African scenario: hospital malnutrition
The broader incidence of adult malnutrition in South African 
hospitals is largely unknown. Only a few studies are available in 
the published literature to date (Table II). The authors are aware of 
ongoing studies that should provide further crucial information once 
such information becomes available. The study populations vary and 
range from groups with high incidences of tuberculosis and human 
immunodeficiency virus (HIV)/acquired immune deficiency syndrome 
(AIDS), to groups who present with lifestyle diseases. Nevertheless, 
the high prevalence of malnutrition is consistent and the evaluated 
nutritional status parameters are known to be associated with higher 
care costs.  
Table I: Costs associated with malnutrition
Study Outcomes
Reilly et al, 198822 Well-nourished and no complications: $2 968 (hospital stay)
Malnourished and complications: $12 683 (hospital stay)
Chima et al, 199723 Not at risk of malnutrition: $4 563 ± 3 702 (hospital stay)
At risk of malnutrition: $6 196 ± 4 585 (hospital stay)
Desport et al, 199924 Mean daily hospital cost per well-nourished patient: $138
Mean daily hospital cost per malnourished patient: $228 
Braunschweig et al, 200025 Normally nourished at admission and discharge: $28 631 ± 1 835
Patients who declined nutritionally, regardless of nutritional status at admission: $45 762 ± 4 021
O’Flynn et al, 200526 Malnutrition costs the NHS in excess of £266 million annually through longer length of stay, readmissions and treatment costs
CEPTON study, 200727 Direct costs of under-nutrition and malnutrition amount to €9 billion/year in Germany
EuroOOPS study, 200828 NRS “at risk”: ↑ mortality (12%); ↑ length of stay in hospital (9 days); ↑ complications (30.6%); ↑ cost
NRS “not at risk”: ↓ mortality (1%); ↓ length of stay is hospital (6 days); ↓ complications (11.3%); ↓ cost
PREDYCES study, 200929 Patients at risk on admission: €8 207
Patients who were not at risk on admission:  €6 798
Patients who developed malnutrition in hospital:  €12 237 
Patients who did not develop malnutrition in hospital: €6 408
NHS: National Health Service, NRS: nutritional risk screening (NRS-2002)
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Infection and sepsis
Approximately 5-10% of patients who are admitted to acute care 
hospitals acquire one of more infection, affecting two million patients 
each year, and resulting in approximately 90 000 deaths annually in 
the USA. This adds an estimated $4.5-5.7 billion per year to the costs 
of patient care.36   
Sepsis, septic shock and the adverse sequelae of the systemic 
inflammatory response syndrome (SIRS) have been shown to be 
the 10th37-13th38 most common cause of death in the USA and the 
second most common cause of death in non-coronary ICUs.37 Sepsis 
is often lethal. It is suggested that the mortality rate is between 
20-50% in severely ill patients37 or 8-90%.38 Only 10% of deaths 
were reported to be related to underlying disease, while 25% were 
attributable to bacteraemia.38  
Costs that relate to care of a patient with sepsis have been described 
to be as much as $50 000 per patient, resulting in an annual burden 
of approximately $17 billion.37 There are approximately 400  000-
500 000 septic episodes annually in the USA.38 The Centers for 
Disease Control and Prevention (CDC) reported a 139% increase 
in the incidence of sepsis over the last 10 years. This occurred 
despite advances in knowledge and technological support.38 Sepsis 
accounts for $5-10 billion of the annual healthcare costs in the USA38 
and is reported to be the cause of 10% of ICU stays.37  
Although similar statistics are not available in South Africa, it is 
consistently documented that patients with infectious complications 
or sepsis have a longer length of stay and require second- and third-
generation antibiotics, both of which have major cost implications. 
It is reasonable to conclude that if nutrition can play a role in the 
management or prevention of infection and sepsis, it will ultimately 
benefit the patient and reduce care costs.
Immunonutrition and pharmaconutrition
Nutrition and the immune system
Nutrition and the immune system interact on various levels and four 
such stages of interaction have been described.7 Stages I (complete 
nutrition) and II (optimising macronutrients and micronutrients) are 
the so-called “passive” stages which aim to supply the immune 
system with essential nutrients. Stages III (active modulation of the 
immune system) and IV (personalised nutrition) involve modification 
of the immune response through immune response modifiers (IRMs) 
that primarily target the pathogen-associated molecular patterns 
(PAMP) expressed by microbial pathogen receptors in the gut and 
involve more active approaches in modulating immune status.7
Immunonutrition and pharmaconutrition in critical illness
In ancient cultures, very few patients survived 72 hours following 
severe illness or trauma. In the modern world, ambulances, 
ventilation, medication and nutrition therapy enable patients to 
survive serious insults and trauma that might have proved fatal. 
Today, some of the major challenges are sepsis and containment 
of the inflammatory response. Despite following strict protocols 
and procedures, including timely screening and assessment, early 
nutrition therapy and meeting nutrient requirements, there is a high 
incidence of complications such as infections and multi-organ failure 
(MOF), as well as malnutrition. The nutrition therapy practitioner is 
left with the question whether it is possible to influence the outcome 
in favour of positive clinical outcomes. Possible proposed solutions 
in the literature, and which are founded on a growing evidence 
base, include the use of nutrients to modulate the acute phase and 
immune response, to prevent oxidative damage, to ensure glycaemic 
control and to provide probiotics to alter the gut environment, as 
well as sufficient energy and protein. Probiotics are used to alter the 
gut environment. Nutrients are also used to provide sufficient energy 
and protein.
The targets of pharmaconutrients are the immune system, muscles 
and intestines. The expected benefits include preservation of 
lean body mass, decreased intestinal permeability, decreased 
proinflammatory response/SIRS, decreased nosocomial infections, 
shorter length of stay, decreased mortality and a decrease in care 
costs. Various nutrients have been suggested or have been shown 
to play a role as pharmaconutrients, including zinc, selenium, 
vitamin E, vitamin C, glutamine, arginine, ornithine-a-ketogluterate, 
fibre/short-chain FAs (SCFAs), prebiotics, probiotics and synbiotics, 
as well as energy and protein.4,39  
Just as antibiotics are organism-specific, all pharmaconutrients 
may not be beneficial in all critically ill patient populations at a given 
time. The effectiveness of a pharmaconutrient may be dependent 
on the stage or category of the acute phase response. For instance, 
the septic patient is in a hyperinflammatory state with SIRS 
predominance, with late predominance of the compensatory anti-
inflammatory response syndrome (CARS) resulting in a second round 
of infections, MOF and death. Typically, trauma and surgical patients 
display CARS predominance early on. Consequent infections result 
in sepsis and death. Therefore, it is clear that different nutrients 
will have different advantages and modulatory effects in these two 
states.20,40-42
Table II: Incidence of adult malnutrition in South African hospitals
Area, year Description of malnutrition
Zululand, 198330 Medical patients:
93% of male and 72% of female patients: Triceps 
skinfold thicknesses < 60% of normal
One third of patients: clinically marasmic
Durban, 198331 Hospitalised urban black patients:
Significantly reduced fat stores: 82% males
Cape Town, 198432 Medical and surgical patients:
Significant body weight depletion: 20% of patients
Significant fat depletion: 30% of patients
Significant muscle depletion: 15% of patients
Cape Town, 198833 Tuberculosis hospital:
Decreased body weight: 32.3% of patients
Fat depletion: 78.8% of patients
Muscle depletion: 37% of patients
Cape Town, 199734 Medical patients:
Severe malnutrition: 17%
Subclinical malnutrition: 77%
Eastern Cape, 201135 Burn patients:
46.3% malnourished at admission
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Energy and protein
Although energy and protein are not commonly described as 
pharmaconutrients, it is well known that protein and energy 
insufficiency results in malnutrition which is associated with an 
impaired immune response and impaired wound healing, both of 
which are in turn associated with infections.43 In the South African 
scenario, where finances are often limited, it is imperative to first 
provide the patient with basic nutrition support that meets the 
patient’s requirements. This includes meeting energy and protein 
requirements through EN, PN or both routes, early EN nutrition 
to support the gut-associated lymphoid tissue (GALT), mucosa-
associated lymphoid tissue (MALT) and modulate cytokines, 
and ultimately optimal feeding. Although this approach will not 
necessarily modulate the immune response, it will at least support 
the immune system. Various other nutrients have been also shown to 
play a role in the immune system, including vitamins, minerals and 
trace elements. Thus, meeting basic requirements is a prerequisite 
for a functional immune system.7
Despite increased awareness and efforts, very few ICUs worldwide 
successfully execute the basics in terms of nutrition support. In a 
study which included 259 ICUs worldwide (n = 5 497 ventilated 
patients), it was shown that when compared with medical patients, 
surgical patients were less likely to receive EN (54.6% vs. 77.8%) 
and more likely to receive PN (13.9% vs. 4.4%) (p-value < 0.0001). 
In patients in whom EN was initiated, on average, surgical patients 
started EN 21 hours later (57.8 vs. 36.8 hours, p-value < 0.0001) 
and received less of their prescribed energy from EN (33.4% vs. 
49.6%, p-value < 0.0001) or from all nutrition sources (45.8% 
vs. 56.1%, p-value < 0.0001) than medical patients.44 Therefore, 
basic principles need to be established and cemented to be able to 
successfully add immunonutrition and pharmaconutrition concepts 
when supporting such patients.
The source of protein that is used in an EN formula may also 
impact on immune function. Whey protein is high in branched chain 
amino acids, particularly leucine, which is known to play various 
roles, ranging from being a substrate for protein synthesis, to a 
modulator of insulin signaling. In addition, whey protein is high in 
cysteine which is the limiting amino acid for glutathione synthesis 
and is necessary for antioxidant defenses. Whey, a “fast” protein, 
preferentially stimulates protein synthesis which potentially makes 
it an excellent source of amino acids in critically ill patients.45 
Gastric emptying of whey-based formula is faster than similar 
casein-based formula46 and may be beneficial in critically patients 
with motility disorders. A comparison of equal volumes of whey-
based formula that had different energy densities and osmolalities 
indicated that they emptied at a comparable rate. This can improve 
nutrient delivery to patients with volume intolerance.46 Preclinical 
studies reported that whey protein also facilitated protein synthesis, 
decreased inflammation, had antioxidant effects and reduced gut-
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reperfusion injury.47 A double-blind randomised controlled trial (RCT) 
compared early EN with a formula containing whey with standard 
EN (containing casein as the protein source) in ischaemic stroke 
patients, and reported that whey may decrease inflammation and 
increase antioxidant defenses.48  
Small peptide EN formulation may also be beneficial as a number of 
studies have reported that at a physiological level these formulations 
are easier to absorb over the gut lumen, result in less feeding 
intolerance and increase protein synthesis at the visceral level 
through increased nitrogen retention. Preclinical studies have shown 
a greater increase in glucagon which may have a positive trophic 
effect on the intestinal mucosa. Animal studies have also shown that 
peptide diets have higher levels of nitrogen retention, higher rates 
of weight gain, higher rates of tissue repair and a positive trophic 
effect on the small bowel mucosa, compared to free amino acid 
formulations.47
However, more human data is necessary to substantiate the claims 
for both whey protein and small peptides based protein sources 
and to strengthen the evidence-base in clinical practice. It should 
nevertheless be noted that these substrates are currently much 
cheaper than pharmaconutrients, are readily available in the South 
African market, and should thus at least be considered in the 
treatment of critically ill patients in the local context.
Glutamine (cell-protective nutrients)
Glutamine is now considered by many investigators to be 
“conditionally essential” in critical illness.49,50 Deficiency can develop 
within 24 hours in this group of patients. It is the most abundant 
free amino acid in the body, but stores are rapidly depleted during 
injury or critical illness. Deficiency states are described in patients 
with trauma, sepsis, surgery and burns.8,50,51 Glutamine serves as a 
metabolic substrate for immune cells and enterocytes, supporting 
barrier and immune function.50 It may also serve as a vital cell-
signalling molecule in states of illness and injury.52  In this regard, 
glutamine has been shown to regulate the expression of many genes 
that relate to metabolism, cell repair and defense, signal transduction 
and activation of intracellular signalling pathways.52 Glutamine 
release could further serve as a “stress signal” to the organism 
to turn on genes that are vital to cellular protection and immune 
regulation.50 An example of the latter is glutamine’s potential key 
role in enhancing the synthesis of heat-shock proteins (HSPs), which 
are essential to cellular recovery following injury, and for protection 
against organ failure.2,50
On the balance of the available evidence, glutamine supplementation 
in critically ill patients is currently recommended by the American 
Society for Parenteral and Enteral Nutrition (ASPEN)/Society of Critical 
Care Medicine (SCCM),53 European Society for Parenteral and Enteral 
Nutrition (ESPEN)54 and the 2009 Canadian Practice Guidelines.55,56 
A 2009 systematic review demonstrated that glutamine 
supplementation of total PN (TPN) reduced mortality by 29%. All EN 
and PN studies showed a 25% reduction in mortality.56 In line with 
these findings, a recent Scandinavian study (n = 413) also found 
a reduction in mortality with intravenous (IV) glutamine.57 However, 
the Scottish Intensive care Glutamine or seleNium Evaluative Trial 
(SIGNET) in 10 centres in Scotland (n = 5 02) showed no significant 
effect of glutamine supplementation of TPN on mortality or infectious 
complications.58 The lack of effect of glutamine in the Scottish trial 
has been attributed to various factors, including the low dose of 
glutamine used (20 g/day), the short period of administration (four 
to five days) and late implementation. Trials with > 0.3g/kg have 
been shown to have better outcomes. The best results were obtained 
using 0.5 g/kg of IV glutamine.59 The available literature suggests 
that glutamine needs to be administered early since deficiency can 
develop within 24 hours. The no-effect of IV glutamine on plasma 
glutathione60 or the innate immune system61 may indicate that 
glutamine exerts its beneficial effects via mechanisms other than 
the immune system, such as HSP induction.  
EN supplementation of glutamine has a significant beneficial effect on 
immunity, as shown in burn patients. In these patients, 26 g enterally 
supplied glutamine resulted in three times less frequent positive 
blood cultures.62 Fourteen days of glutamine supplementation via 
the EN route (0.5 g/kg/day) significantly increased serum glutamine 
levels,63,64 as well as plasma pre-albumin and transferrin levels.64 
In thermal injury, a setting that is associated with suppressed 
cellular immunity, glutamine supplementation significantly improved 
various measures of cellular immunity, but had no effect on humoral 
immunity.63 Hospital stay in such patients was significantly reduced 
in both studies and wound healing was faster.63,64 EN glutamine 
supplementation in other groups of critically ill patients has been less 
Table III: Glutamine for specific patient populations: clinical practice recommendations53,56,69
Patient population CCCPG ASPEN/SCCM ESPEN
General No recommendation Possible benefit (B)* No recommendation
Elective and major surgery No recommendation No recommendation No recommendation
Trauma Possible benefit Possible benefit (B)* Benefit (A)**
Sepsis No recommendation No recommendation No recommendation
Burns Possible benefit Possible benefit (B)* Benefit (A)**
ALI/ARDS No recommendation No recommendation No recommendation
ALI: acute lung injury, ARDS: acute respiratory distress syndrome, ASPEN: American Society for Parenteral and Enteral Nutrition, CCCPG: Canadian Critical Care Practice Guidelines, ESPEN: European Society for 
Clinical Nutrition and Metabolism, SCCM: Society of Critical Care Medicine 
Grading (A, B) based on level of evidence: American Society for Parenteral and Enteral Nutrition/Society of Critical Care Medicine53 and European Society for Clinical Nutrition and Metabolism69 grading
*ASPEN: Grade B recommendation: supported by one level I [large, randomised trials with clear-cut results, low risk of false-positive (alpha) error or false-negative (beta) error] investigation
**ESPEN: Grade A recommendation: (Ia) meta-analysis of randomised controlled trials, or (Ib) at least one randomised controlled trial
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beneficial, possibly due to the low dose administered and ingested 
for a clinical effect to be documented, as shown by Soquel et al.65
Considering the strength of the evidence base, the administration 
of glutamine in defined critical care settings (Table III) should be 
standard practice in the South African context. Large, multi-centre 
RCTs are currently underway which will provide further clarify and 
better define glutamine requirements in critically ill patients.66-68
Arginine (immune-modulating nutrients)
As the evidence base expanded, the hype surrounding arginine as 
a pharmaconutrient included initial optimism, followed by severe 
caution, to having a definite and appropriate place in the critical care 
setting. Arginine can enhance immune parameters, e.g. lymphocyte 
function, after trauma and surgery, and has been shown to improve 
wound healing.70,71 On the other hand, very little benefit and perhaps 
harm has been observed in septic patients.72-74 Arginine may enhance 
the systemic inflammatory response in septic patients. This results 
in increased mortality.72,75 This is a clear example that the “one 
nutrition therapy regimen will fit all” approach is not appropriate in 
the critical care setting.
Arginine plasma levels have been shown to be significantly reduced 
in surgical and trauma patients, but not in septic patients.76 Arginase 
levels are only modestly increased in septic patients, as compared 
to the significant increase that is seen in trauma patients.8,77 During 
sepsis, there is a classic macrophage response and a maximum 
increase in inducible nitric oxide synthase (iNOS), interleukin (IL)-1 
and T-helper cell 1 cytokine proliferation [interferon-γ, IL-1, tumour 
necrosis factor (TNF)]. In trauma, the alternative macrophage 
response results in significant arginase increase, IL-10 and T-helper 
2 cell cytokine proliferation (IL-4 and IL-13).70,78 Thus, clinical benefit 
has not been demonstrated for the use of arginine in septic patients.
Two recent systematic reviews in surgical patients demonstrated 
a reduction in infectious complications, length of stay and 
postoperative infections with arginine supplementation.79,80 These 
two reviews reported no harm in surgical patients. The Drover et 
al systematic review on perioperative supplementation of arginine 
(it included 35 trials) supports a significant treatment effect of 
arginine therapy following elective surgery.79 Arginine-supplemented 
diets were associated with considerably reduced overall infectious 
complications when compared with standard formula in surgical 
patients [28 trials included; relative risk (RR) = 0.59, 95% 
confidence interval (CI), 0.50-0.70, p-value < 0.00001, I2 = 26%)]. 
Overall hospital length of stay, aggregated across 29 studies, was 
reduced in surgical patients receiving arginine-supplemented diets 
when compared with patients receiving standard formula [weighted 
mean difference (WMD) = -2.38; 95% CI, -3.39 to -1.36; p-value 
< 0.00001; I2 = 87%]. Arginine-supplemented diets did not have a 
significant effect on mortality.
Considering the evidence-base, arginine supplementation should 
be standard practice where safe and appropriate (for surgery and 
trauma) in the South African context.
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Omega-3 fatty acids (anti-inflammatory nutrients)
Fish oils decrease the production of pro-inflammatory mediators.81 
The anti-inflammatory properties occur through three principle 
mechanisms: displacement of arachidonic acid in cell membranes, 
prostaglandin E3 and LTB4 production, decreased nuclear factor-
kappa B (NF-κB) and AP-1 activation.81 Omega-3 FAs (ω-3 FAs) 
have also been shown to decrease the production of nitric oxide 
(NO) via downregulation of iNOS protein expression.81,82 Although 
the inclusion of ω-3 FAs in nutrition therapy makes theoretical 
sense and the potential mechanisms are fairly clear, the data for the 
implementation of such nutrient therapy in critically ill patients are 
much less concrete.
Of particular interest in the critically ill patient is the effect of ω-3 FAs 
on the adult respiratory distress syndrome (ARDS). An EN product 
that contains fish oils, borage oil and antioxidants is recommended 
by the Canadian Practice Guidelines 2009 for the treatment of 
ARDS.55,56 Three studies with the said product as active intervention 
in patients with diagnosed ARDS have shown a reduction in 
pulmonary neutrophils, an improvement in oxygenation, decreased 
severity of ARDS, decreased ventilator days, decreased length of stay 
in ICU and length of stay in hospital and decreased lung cytokine and 
protein secretion.83-85 Despite these positive results, some concerns 
were raised regarding the studies. These included the fact that the 
control groups received high-fat formula, some studies did not have 
an intention-to-treat design and it was difficult to conclude whether 
it was the fish oil or other constituents in the formula that exerted the 
reported positive outcomes.  
Three recent studies complicated the interpretation of findings even 
further. A multi-centre study in Brazil (INTERSEPT study, 14 ICUs, 
n = 200) used the same product (as described above) for seven days in 
patients in the early stages of sepsis and with no organ failure. Although 
there were significant effects on some secondary outcomes such as 
length of stay in hospital and lenght of stay in ICU (LICU), there was no 
effect on mortality.86 It is important to note that the fish oil-containing 
product was used for prevention, and not as treatment, and that once 
more, the other nutrients may also have exerted beneficial effects. No 
benefit of the same product was found in a RCT in 11 Spanish ICUs 
(n = 89) in patients with a diagnosis of sepsis on admission.87 The Early 
versus delayed Enteral Feeding (EDEN)-OMEGA study investigated 
whether ω-3 FAs improved ventilator free days. In this multi-centre 
RCT (44 centres, n = 272) patients received EN supplementation 
(twice daily) of ω-3 FAs, γ-linolenic acid and antioxidants compared 
with an isocaloric control, within 48 hours of developing acute lung 
injury (ALI). It is important to note that this was administered as a 
bolus, whereas in the other studies the patients received continuous 
EN nutrition. The supplementation did not improve the primary end-
point of ventilator-free days or other clinical outcomes in ALI, and 
the practice may have been harmful. Sixty-day-hospital mortality 
was 26.6% in the ω-3 supplemented group vs. 16.3% in the control 
group (p-value = 0.054). Adjusted 60-day mortality was 25.1% and 
17.6% in the ω-3 and control groups, respectively (p-value = 0.11). 
The study was terminated early because of futility.88 In a phase II RCT 
in five North American centres (n = 89) the addition of fish oil did 
not reduce the biomarkers of pulmonary or systemic  inflammation 
in ALI. In this case, the fish oil was supplemented as a bolus as 
a single nutrient [9.75 g eicosapentaenoic acid (EPA) and 6.75 g 
docosahexanoic acid (DHA) daily]. The researchers concluded that 
the results did not support the conduct of a larger clinical trial in this 
population with this particular agent.89  
Heterogeneity of studies investigating the supplementation of EN 
fish oils complicates decision-making on the part of the nutrition 
therapy practitioner and makes the drawing of firm conclusions 
difficult. Although many of these studies have robust study designs, 
in many cases the study design, method of administration (bolus 
vs. continuous) and disease (established ARDS vs. ALI vs. sepsis) 
differed and single or mixed nutrients were investigated. However, it 
seems that bolus administration of fish oils is harmful in this group 
of critically ill patients and should not be practised.
Guidelines with regard to the use of PN lipids differ between the 
North American and European organisations. ESPEN recommends 
the use of lipid emulsions as part of TPN,54 while ASPEN and the 
Canadian guidelines recommend TPN without soy-based lipids.53,55,56 
The difference in these guidelines can probably be attributed to the 
regional availability of lipid sources (ω-3 containing lipid sources is 
not yet available in North America). The Canadian Practice Guidelines 
2009 further state that there is insufficient evidence to draw a 
conclusion as to the type of lipid to be used in critically ill patients 
on TPN.  
Four small recent studies using ω-3 FA containing PN had different 
interventions (ω-3 FAs as part of PN or supplemented PN ω-3 FAs). 
Although there was some indication of a reduction in mortality, no 
effect on infectious complications was documented.90-93 A significant 
reduction in procalcitonin levels was found in the study by Khor et 
al, suggesting that fish oil attenuates the inflammatory process.92 
A small study (n = 16) compared a standard PN lipid emulsion to 
a lipid emulsion containing ω-3 FAs in patients with ARDS. The 
fish oil-supplemented PN resulted in a beneficial alteration in lipid 
mediator profiles,94 the clinical significance of which still remains to 
be confirmed. A third-generation lipid emulsion containing soybean, 
medium-chain triglyceride, olive and fish oils (SMOFlipid) resulted 
in favorable FA profiles (a desirable reduction in the ω-6/ω-3-FA 
ratio)95 and retained hepatocellular integrity.96 Small trials showed 
that fish oil- (ω-3) supplemented PN had anti-inflammatory and 
hepatoprotective effects in hyperinflammatory disease such as 
sepsis,97 a beneficial effect on PN-associated liver disease,98 reduced 
the Acute Physiology and Chronic Health Evaluation (APACHE) II 
and Simplified Acute Physiology Score II, as well as procalcitonin 
in sepsis.92 However, clearly larger trials are required to confirm 
the findings or form the basis for recommendations in practice. A 
systematic review (six trials were included) concluded that PN lipid 
emulsions that contain fish oil had no mortality advantage, but 
significantly reduced infectious complications (p-value = 0.03). 
There was a trend towards shortening hospital length of stay by 
3.06 days (the exclusion of a heterogeneous study showed a 
significant reduction), and significantly reduced ICU length of stay by 
2.07 days.99 The authors of the systematic review further concluded 
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that although insufficient data precluded a conclusive economic 
advantage, the possibility of cost reduction existed,99 a conclusion 
that remains to be confirmed in clinical practice.   
Considering the current evolving evidence base and available 
guidelines, ω-3 FAs should be considered to form part of PN 
lipid emulsions, at least for their effect on lipid profiles and PN-
associated liver disease as discussed above, but strengthening 
of the evidence base is needed to reach firmer conclusions. EN 
omega-3 FA supplementation [fish-oil derived ω-3 FAs (EPA and 
DHA), borage oil and antioxidants] administered in the context of 
an immune-enhancing diet is currently recommended specifically 
for patients presenting with ALI and ARDS by ASPEN/SCCM (Grade 
A recommendation),53 ESPEN (Grade B recommendation)69 and the 
2009 Canadian Practice Guidelines.56  
Micronutrients
Critical illness is associated with increased production of reactive 
oxygen species and oxidative stress, and low levels of most 
micronutrients, with resultant diminished endogenous antioxidant 
defenses.100  The inherent antioxidant potential is overwhelmed in 
critically ill patients, resulting in cell damage, the SIRS response 
and increased morbidity and mortality in critically ill patients.81 
Micronutrient supplementation is thought to be beneficial to critically 
ill patients by ameliorating oxidative stress and by improving clinical 
outcomes.
Research on micronutrient supplementation in the critically ill has 
focused mainly on five micronutrients: selenium, zinc, copper, 
vitamins C and E. Individual studies have investigated the vitamin 
B group.100 The aims of supplementation can be described as 
provision of basic nutritional support (bearing in mind the increased 
requirements due to hypermetabolism and wound healing), the 
prevention and correction of deficiencies and modulation of the 
APR and immune responses through reinforcement of endogenous 
antioxidant defenses. 
Trials in patients with thermal injury have focused mainly on 
selenium, zinc and copper, after low blood concentration of these 
micronutrients had repeatedly been shown in this patient population, 
as well as the known uniqueness of this group of patients in terms of 
the extensive cutaneous losses of these micronutrients.101-104 Berger 
et al consistently demonstrated in a series of well controlled trials 
that trace element supplementation reduces infectious complications 
in burn patients. Supplementation (IV) of copper 2.5-3.1 mg/day, 
selenium 315-380 μg/day, and zinc 26.2-31.4 mg/day for eight to 
21 days resulted in a significant reduction in the number of infections. 
This related to a significant reduction of nosocomial pneumonia 
(p-value < 0.001) and of ventilator-associated pneumonia (p-value = 
0.023).105 This is in agreement with the authors’ previous data which 
showed that trace element supplementation resulted in a significant 
reduction in bronchopneumonia infections and consequent shorter 
hospital length of stay.106 Patients receiving 59 μmol Cu, 4.8 μmol 
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Se, and 574 μmol Zn per day (IV) demonstrated a significantly 
improved clinical course, including better graft take and fewer 
infectious complications. Supplementation was again associated 
with a significant reduction in infectious complications, especially 
bronchopneumonia.107
A growing body of evidence is emerging that demonstrates the 
potential benefits of micronutrient and specifically antioxidant 
micronutrient supplementation in critically ill patients. A recent 
systematic review included 15 RCTs involving 1 714 participants 
(primary objectives) and 18 RCTs involving 1 849 participants 
(secondary objectives).100 This updated review concluded and 
supported previous findings108 that micronutrient supplementation 
in the critically ill may be associated with a decrease in overall 
mortality [RR 0.78, 95% CI 0.67-0.90, I2 = 0%, p-value = 0.0009] 
and more specifically in 28-day mortality (RR 0.75, 
95% CI 0.63-0.88, I2 = 0%, p-value = 0.0006). 
Micronutrient supplementation in this updated 
review was not associated with a decrease in 
infectious complications, similar to the findings of 
Heyland et al.108 This finding could possibly indicate 
that the observed mortality effect was mediated by 
other mechanisms, e.g. increased organ function. 
The updated review was the first to report on 
LICU and length of stay and concluded that these 
outcomes were unaffected by micronutrient 
supplementation. A sensitivity analysis of 
combined micronutrient supplementation indicated 
a significant reduction in mortality (RR 0.69, 95% 
CI 0.54-0.90, I2 = 2%, p-value = 0.006). Although in 
contrast to the findings of the previous systematic 
review108 (i.e. single nutrients were associated 
with a significant decrease in mortality, combined 
micronutrients were not), this new finding of the 
updated review supports prior hypotheses and the 
rationale underlying the use of combinations of 
micronutrients, namely the biochemical properties 
of the endogenous antioxidant network and 
micronutrients’ interdependence for regeneration 
of antioxidant defenses.109 This updated systematic 
review did not find clear evidence that PN was 
superior to EN administration in terms of clinical 
outcomes. The authors recommended that future 
studies could investigate the use of PN and EN 
administration of micronutrients to maximise the 
opportunity of demonstrating a treatment effect, if 
Table V: Approximate ICU costs per day*
A. Standard high care postoperative costs (12 hours)
High care bed (R7 000.00/day)     3 500.00
Enoxaparin 40 mg SC X 1 76.80
Morphine 15 g 5 amps 23.96
Metoclopramide 10 mg 1 amp 2.50
Paracetamol 1 g 2 amps 130.00
Cefazolin 1 g 2 amps 25.60
TOTAL (High care bed and medication) R3 758.86
B. ICU costs and medication (treatment of complication)
ICU bed only, excludes ventilation     10 000.00
Phenylephrine (10 mg/ml) 1 ml X 30 1 807.00
Enoxaparin 40 mg SC X 1 76.80
Esomeprazole 40 mg IV X 1 186.57
Caspofungin 50 mg IV X 1 2 401.22
Imipenem-cilastatin 500 mg IV X 8 1 982.05
Linezolid 600 mg IV X 2 997.92
Amiodarone 200 mg NGT X 3 51.63
Morphine 15 g 10 amps 47.93
Metoclopramide 10 mg 3 amps 7.50
Remifentanil 5 mg X 5 2 508.00
TOTAL (ICU bed and medication) R20 066.62
C. Enteral nutrition + IV glutamine
Semielemental feed 2 litres X 1 511.64
IV glutamine 200 ml X 1 738.81
TOTAL (Enteral nutrition + IV glutamine) R1 250.45
 * These are approximate costs in one setting (Gauteng private hospital; 2012) used as an example only
(R20 066.62 x 3 days = R60 199.86)
Table IV: Supplemented antioxidant nutrients, vitamins and trace elements53,54,56
CCCPG ASPEN/SCCM ESPEN
Based on three level I, and 13 level II studies, the 
use of supplemental combined vitamins and trace 
elements should be considered in critically ill 
patients.
Combination of antioxidant vitamins and trace 
minerals, specifically including selenium, should 
be provided to all critically ill patients receiving 
specialised nutrition therapy.
(Grade B recommendation)
All PN prescriptions should include a daily dose of 
multivitamins and trace elements. 
(Grade C recommendation)
Insufficient data to make a recommendation 
regarding IV/PN zinc supplementation in critically 
ill patients.
RDA vitamins, minerals and trace elements.
Insufficient data to make a recommendation 
regarding IV/PN selenium supplementation alone, or 
in combination with other antioxidants, in critically 
ill patients.
Thiamine 100-300 mg/day for the first three days 
(deficiency states). 
(Grade B recommendation)
ASPEN: American Society for Parenteral and Enteral Nutrition, CCCPG: Canadian Critical Care Practice Guidelines, ESPEN: European Society for Clinical Nutrition and Metabolism, IV: intravenous, PN: parenteral 
nutrition, RDA: recommended dietary allowance, SCCM: Society of Critical Care Medicine
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one really exists. The secondary outcomes of this review confirmed 
that timing, duration and dosing are key factors to ensure optimal 
clinical benefit.100 
The latest systematic review, including 21 trials, regarding 
antioxidant micronutrients in the critically ill confirm the mortality, 
length of stay and LICU findings by Visser et al,100 and additionally 
report a significant reduction in duration of mechanical ventilation 
(WMD in days = -0.67, 95% CI -1.22 to -0.13, p-value = 0.02) with 
antioxidant supplementation.110 Furthermore, antioxidants were 
associated with a significant reduction in overall mortality in patients 
with higher risk of death (> 10% mortality in control group) (RR 
0.79, 95% CI 0.68-0.92, p-value = 0.003), whereas no significant 
effect was observed for trials of patients with a lower mortality in 
the control group.110 
The Cochrane Database Systematic Review by Avenell et al (updated 
2007) investigating the effects of single-nutrient supplementation, 
specifically selenium supplementation, including the selenium-con-
taining compound ebselen, concluded: “There is limited evidence 
to recommend supplementation of critically ill patients with sele-
nium or ebselen”.111 They found no significant differences for overall 
mortality and infectious complications and no clear evidence of the 
benefits of such supplementation for ventilator days, LICU, length 
of stay or quality of life. However, they did find that the evidence 
was more suggestive of a benefit on mortality in the first month for 
general ICU patients when compared with those with severe pan-
creatitis (p-value = 0.02). The more recent SIGNET trial58 found that 
500 μg selenium daily as part of PN in critically ill patients signifi-
cantly decreased new infections in a subset of patients who received 
the supplement for ≥ 5 days, but it did not affect mortality. When the 
SIGNET trial data58 for selenium supplementation were entered into 
the current Cochrane systematic review,111 the random effects risk 
ratio for mortality changed from 0.75 (0.59-0.96, I2 = 0%) to 0.86 
(0.74-1, I2 = 0%), and the risk ratio for new infections changed from 
1.22 (0.67-2.23, I2 = 0%) to 0.93 (0.79-1.09, I2 = 0%).111
In one older study, high-dose vitamin C administration during 
resuscitation (66 mg/kg/hour) was shown to attenuate lipid 
peroxidation and reduce resuscitation fluid requirements, as well as 
post-burn oedema. The length of mechanical ventilation was also 
significantly reduced and improved early respiratory function was 
observed.112
Other micronutrients that have received attention in recent years 
include vitamin D and vitamin B12. Vitamin D deficiency states have 
been described in patients with severe sepsis and other critically 
ill populations113,114 with low levels of vitamin D-binding hormone 
being reported.115 Studies of vitamin D replacement studies in the 
critically ill have mainly considered short-term outcomes and have 
generally led to increases in vitamin D levels.116,117 Whether the latter 
translates into meaningful clinical outcomes remain to be seen. 
It is unclear whether low levels of vitamin D contribute to critical 
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illness or are just a marker of illness severity. The outcomes of 
large clinical trials that investigated vitamin D supplementation are 
currently awaited. It is proposed that future studies should examine 
vitamin D as well as important metabolites of vitamin D, their binding 
proteins and parathyroid axis. The potential benefit of IV vitamin B
12 
supplementation as a pharmaconutrient in critically ill patients has 
been described,118 but clinical intervention trials studying vitamin 
B12 as a pharmaconutrient strategy in the critical care setting are 
awaited. One recent observational study indicated an increased 
mortality rate in patients with Vitamin B
12 levels over 900 pg/ml 
(p-value < 0.0002).119 Nutrition therapy practitioners should always 
bear in mind that “much more is not necessarily better” and that 
some micronutrients have or may have a narrow therapeutic window 
when high-dose supplementation is being considered. Furthermore, 
in this group of patients the potential exists for the creation of a pro-
oxidant microenvironment with deleterious patient outcomes. This 
should always be borne in mind.
Establishing exact micronutrient requirements in the critically ill has 
proven to be notoriously difficult. Various general sets of guidelines 
are available (Table IV). Despite these guidelines, little consensus 
exists as to what to use when, and many questions remain 
regarding required doses, routes and timing of replacements or 
supplementation.
Providing micronutrients to include the full range of trace elements 
and vitamins is an integral part of nutritional support. In practical 
terms in the South African context, it is clear that micronutrients 
should be provided at least at the current available recommended 
doses to prevent overt clinical deficiencies. For other claims, 
indications and higher doses, the literature consistently indicates 
that the ratio of risk (adverse effects) to benefit (mortality) may be 
favourable, and if such higher doses are used in practice, it should 
be within the dose range that the current experience covers, and for 
the clinical settings studied only.
Finally, the bigger picture should always be considered, bearing 
in mind the complexity of the acute phase response and the vast 
heterogeneity of the critical care population. Optimal nutrition 
therapy includes all relevant components, including attention to 
energy, protein, carbohydrates, lipids, fluids, fibre and the discussed 
immunonutrients and pharmaconutrients, in the right mix, at the 
right time, to the right patients, to ensure optimal clinical benefit 
and outcome.
Cost considerations
Considering the evidence base, sets of guidelines are available for 
the implementation of immunonutrition and pharmaconutrition in 
appropriate circumstances. But often, and specifically also in the 
South African setting, the final verdict regarding implementation 
is determined by cost. The available evidence on the benefits of 
and cost containment by nutrition therapy should not only be seen 
within the context of the limitations of the studies being reported 
and the regional variation of costs, but also within the context of the 
consistency of the reported benefits.  
Basic nutrition therapy costs have been reported to be US$20-
40 per day (EN nutrition), while PN nutrition costs US$55-200 per 
day. In addition, antibiotic therapy has been reported to amount to 
approximately US$65-US$1 345/day. 120
Already in 1997, it was shown that an immune-enhancing formula 
containing arginine not only significantly reduced late postoperative 
events in patients undergoing gastric surgery, but also reduced 
the costs of treating complications (83 563 Deutsche Mark in the 
experimental diet group vs. 122 430 Deutsche Mark in the control 
group, resulting in a cost-reduction of 38 867 Deutsche Mark).121 
In a more recent study, the projected investment and cost savings 
using arginine-containing formula for 1 000 well-nourished surgery 
patients, with a 20% base infection rate, was US$45 000 and 
US$1 442 000 respectively. The projected investment and cost 
savings using arginine-containing formula for 200 malnourished 
surgical patients, with a 20% base infection rate, was US$44 000 
and US$272 400 respectively.  Finally, the projected investment 
and cost savings using arginine-containing formula for 200 trauma 
patients, with a 60% base infection rate, was US$35 000 and 
US$759 400 respectively.122
Recently, a simulation study, incorporating outcome rates from 
200 Italian ICUs for over 60 000 patients, was conducted to 
determine whether PN alanyl-glutamine supplementation (compared 
to standard TPN) in critically ill patients had the potential to partially 
or totally offset its own costs by reducing the consumption of other 
medical resources. The glutamine-supplemented TPN resulted in 
a reduced mortality rate (26.4 ± 1.6% vs. 34.5 ± 2.1%), reduced 
infection rate (13.8 ± 2.9 vs. 18.8 ± 3.9%) and reduced hospital 
length of stay (24.9 ± 0. 3 days vs. 26.0 ± 0.3 days). More importantly 
in this context, it resulted in a lower total cost per patient (€23 409 
± €3 345 vs. €24 161 ± €3 523). The treatment cost was completely 
offset by savings on ICU and antibiotic costs. 123 
A comparison of conventional vs. preoperative immunonutrition in 
gastrointestinal cancer patients resulted in a total nutrition cost of 
€3 407 in the conventional group and €14 729 in the supplemented 
or preoperative group. In patients without complications, the in-
hospital routine care was similar, but the mean cost of complication 
per patient in the conventional group was €6  178, compared to 
€4 639 in the preoperative group (p-value = 0.05). The total cost of 
patients with complications was €535 236 in the conventional group 
and €334 148 in the preoperative group. Cost-effectiveness (analysis 
performed by dividing per-patient costs of clinical nutrition and 
costs of treating postoperative complications with the percentage 
of complication-free patients; thus, the cost of achieving one 
complication-free patient per group) was €6 245 in the conventional 
group and €2 985 in the supplemented group.124
To the authors’ knowledge, there are no comparative cost data in 
South Africa. A simple approximate cost calculation rather than 
an economic analysis, (only including ICU bed and medication 
but excluding the cost of ventilator support, IV fluids and medical 
and allied professional fees) was undertaken (as an example) to 
determine the cost of one day for a high care (no complications), 
a critically ill patient in the ICU (with complications) as well as the 
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approximate cost of one day of enteral feeding with a semielemental 
formula plus 200 ml IV glutamine (Gauteng private hospital setting 
protocols and costs) (Table V). The costs were calculated for an 
elderly, well-nourished patient, who had a knee replacement and 
developed complications (sepsis and atrial fibrillation; treated with 
second- and third- generation antibiotics and an antifungal agent), 
who needed ventilation. Standard costs, if the patient did not develop 
complications for 12 hours in a high care unit (standard protocol) 
would have been R3 758.86 (Table V, Section A). In this example 
and in comparative terms, the standard (semielemental) feed as well 
as specialised (glutamine) nutrition therapy, alone or in combination 
(Table V, Section C), can be seen as relatively “minor” compared to 
the costs, in the same patient, of medication necessitated by the 
complication described in the example (Table V, Section B). If the 
assumption was also to be made that preventive nutrition support/
therapy would have significantly reduced the risk of the complication 
that was encountered for a total costs of R5 009.31 (Table V, Sections 
A and C), the approach would have still achieved significant costs 
containment in comparison to the costs of treating the specific 
complications in the example used.  
Bearing in mind that some studies have indicated that LICU can be 
shortened by two to three days with IV glutamine, when needed, 
the authors compared the cost of seven days of IV glutamine 
(R 738.81 x 7 = R5 171.67) vs. three extra ICU days (R 20 066.62 
x 3 = R60 199.86) in order to highlight the cost containment a 
pharmaconutrient-based nutrition therapy approach has to offer in 
the appropriate setting (the authors concede the theoretical nature 
of the example and the assumptions made therein).   
Amid a growing and strengthening evidence base supporting benefit, 
and clear indications of outcome benefits, as well as potential cost 
savings, critical care nutrition guidelines have been developed to 
help busy practitioners decide how to feed their critically ill patients. 
Despite good adherence to some recommendations, large gaps 
exist between many current recommendations and actual practice 
in ICUs, and consequently, nutrition therapy is still suboptimal.125 
Knowledge-to-action models need to be explored and implemented 
to optimise nutrition therapy at the bedside.126
Conclusion
The value of immunonutrition formula in the management of critically 
ill and preoperative and postoperative patients is now acknowledged 
by many nutrition therapy and medical practitioners. Amid the 
demonstration of clear clinical and cost-containment benefit in 
defined conditions, South African practitioners should also aim to 
close the knowledge-to-best-practice gap to optimise nutrition 
therapy and ultimately, clinical outcome in critically ill patients. It 
is clear that continued clinical research is necessary for an even 
better understanding of immunonutrition and pharmaconutrition 
approaches. Specifically, large, multi-centre, prospective RCTs 
that evaluate each immune-modulating nutrient individually, as 
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well as in various combinations, at various doses, and in defined 
patient populations, would lead to better evidence-based practice 
guidelines.127 A few such trials are already underway. In future, 
a paradigm shift to pharmaconutrition is gaining momentum, a 
practice which dissociates the administration of key single nutrients 
in the form of requirement-based PN or EN nutrition from the delivery 
of pharmaconutrients in the full effective pharmacological dose, as 
evaluated in large, well designed trials, in order to achieve therapeutic 
effects.1 The current use of clinical pharmacology, molecular biology 
and clinical research principles in the study of pharmaconutrients 
should provide further answers on how to administer the right 
nutrients, in the right doses, at the right time, in critically ill patients.2
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